MNOV
What one share of Medicinova holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market.
Medicinova’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$0.22 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.19 |
| Cash and investments | $0.52 |
| Book value | $0.76 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.33 | $0.00 | −$0.20 | — | $1.00 |
| 2017 | — | −$0.32 | — | −$0.20 | — | $1.06 |
| 2018 | — | −$0.36 | $0.00 | −$0.22 | — | $1.74 |
| 2019 | — | −$0.30 | $0.00 | −$0.21 | — | $1.71 |
| 2020 | — | −$0.31 | $0.00 | −$0.24 | — | $1.58 |
| 2021 | $0.08 | −$0.21 | $0.00 | −$0.19 | — | $1.71 |
| 2022 | — | −$0.29 | $0.00 | −$0.26 | — | $1.43 |
| 2023 | $0.02 | −$0.17 | $0.00 | −$0.15 | — | $1.27 |
| 2024 | — | −$0.23 | $0.00 | −$0.22 | — | $1.07 |
| 2025 | $0.01 | −$0.24 | $0.00 | −$0.20 | — | $0.84 |